Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743465 · ClinicalTrials.gov registry record
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
A clinical trial of Leukemia, sponsored by Takeda.
- Completed
- Registry status
- 1,769
- Enrollment target
- 1
- Study location
NCT05743465: Completed study of Leukemia, sponsored by Takeda.
NCT05743465 is a study of Leukemia that has completed, run by Takeda. The registered enrollment target is 1,769 participants, above the 479-participant average among 233 other Leukemia trials with a reported enrollment target (269% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05743465, a study of Leukemia, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 1,769 participants
- Enrollment target
- 1
- Study location
Study Summary
The aims of this study are to learn out about treatment information (including amongst others treatment patterns, safety, development of a participant's condition) ponatinib, bosutinib, imatinib, dasatinib and nilotinib using already available data. No new data will be collected from participants as part of this study and no study medicines will be provided in this study.
Primary Outcome
Socio-demographic variables included will include categories of Age (in years), Sex (male and female), and US geographic region.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Massachusetts
- Takeda - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,769 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2022-11-30 |
What the finished NCT05743465 record still lists
NCT05743465 is an observational study that tracks outcomes without assigning an intervention. Its 1,769 participants enrollment target places it among the larger protocols in the corpus, above the 479-participant average among 233 other Leukemia trials with a reported enrollment target (269% higher).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT05743465 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05743465 about?
NCT05743465 is a clinical study titled "A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia". The aims of this study are to learn out about treatment information (including amongst others treatment patterns, safety, development of a participant's condition) ponatinib, bosutinib, imatinib, dasatinib and nilotinib using already available data. No new data will be collected from participants as...
What is the current status of trial NCT05743465?
This trial is currently completed. The enrollment target is 1,769 participants. The study started on 2021-10-06. Estimated completion is 2022-11-30.
What conditions does trial NCT05743465 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT05743465?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05743465?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05743465 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05743465's enrollment target sits among peer trials
1,769 7th of 233 higher than 227 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT06872892 · 1,755 participants · Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI